A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. - Test2 - elhamkhani - TriplyDB

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

http://www.wikidata.org/entity/Q37200466

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells The interconnectedness of cancer cell signaling.A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.Minireview: epigenetic changes in ovarian cancer.Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.The War on Cancer rages on.Epigenetics of neurological cancers.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?Modelling the microtubule: towards a better understanding of short-chain fatty acid molecular pharmacology.Role of epigenomics in ovarian and endometrial cancers.Modulation of gene expression in ovarian cancer by active and repressive histone marks.The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.

P2860

Q24628746-25EF7BBE-1216-4A4D-BF93-445E3337384B Q28535153-31DF2A1A-F792-4146-BEFF-1267BFE9B680 Q30464276-FBCC93A0-1895-4EDE-893B-C666CE874C9F Q33588300-C278D009-FE39-46F6-92FF-605AB146E241 Q33621141-24FB6FDF-3547-4268-B5C5-795367CA38DB Q35556954-7C41D600-55C1-4262-BD7C-581FF8FB7258 Q35669733-4A3E67CF-9C56-4002-845D-A2FF48A3F3AB Q36129967-4E87C26C-EF43-43FB-A92F-6FE03D7AD79F Q36256343-955E82FB-C3AC-4877-BE05-BE23D75B6C4C Q37328836-25201F17-4FC8-4C2D-9651-8469144F6DCF Q37447349-34EC9E34-DFB5-47BF-8D77-983B896A6473 Q37478602-6262CE1B-6721-4664-AC33-A922605D3C57 Q37650610-E5853DD1-1BB9-413B-B528-51E401A726A5 Q37702543-318620B2-22B5-42AF-9788-9CE8383F7176 Q37833936-C0C9557F-87DD-4E2B-8D48-355A0D4FA88B Q37961734-39230139-3076-4B92-927E-D5ECC8412DFC Q37962015-928D1491-7161-4379-B01D-3B4771F582FB Q38717140-92F64224-D3F9-451E-B871-EAA1DA1C82A7 Q39165456-7FB0DC18-FA85-49CE-9C32-0013BC4DD33D Q39244903-4DB8346C-3758-474A-95B2-F42810D7C811 Q39581390-8BD3B549-7475-417E-8881-03FFB21A7D0B Q39632688-68088963-CF7D-4474-BC88-CC71FEE701C6 Q39695495-EB610844-334F-4863-9635-67283158049E Q40084337-68689115-9DF2-41E0-A7A1-43A393E4ED0E

P2860

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

http://www.wikidata.org/entity/Q37200466

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A rationally designed histone ...... tivity against ovarian cancer.

@en

A rationally designed histone ...... tivity against ovarian cancer.

@nl

type

label

A rationally designed histone ...... tivity against ovarian cancer.

@en

A rationally designed histone ...... tivity against ovarian cancer.

@nl

prefLabel

A rationally designed histone ...... tivity against ovarian cancer.

@en

A rationally designed histone ...... tivity against ovarian cancer.

@nl

P1433

Q37200466-ABF58507-9321-4ECD-AED8-332242A0A902

P1476

Q37200466-AC468C9A-18C9-466B-B2A7-21BCD02475F7

P2093

Q37200466-00A57E81-CB06-4123-A3A3-7C1020575DEE

Q37200466-1887B1F3-0195-4AC0-BD91-B35565A67E84

Q37200466-72EA6568-5BA4-4070-825F-E197E4FADF87

Q37200466-7D4D137D-337A-44B4-B5DF-60FC42A68AF2

Q37200466-9A5B89E8-A78B-4C58-B6F9-5A85AF5BA398

Q37200466-F76C36AA-F4F1-4909-99F5-FF34FCE46864

P2860

Q37200466-04255A2D-82C1-4077-8870-F4AD4E675FFD

Q37200466-0D06ADBD-8BE1-477C-9E07-F5A96091DA6A

Q37200466-104648EE-086A-4C4F-83FE-E2D8A07F3DCE

Q37200466-10872D0A-6AA3-4723-B72C-24C1704727E0

Q37200466-12C39EA4-7CDC-452E-9763-1397016F58E1

Q37200466-1A8F3FC2-3DDD-40A6-813D-F6563384C1B8

Q37200466-1DFA6E20-8E0B-4DF5-BAC9-8FFDD6906889

Q37200466-1F15D4B4-F77B-4DFB-97FB-368EBE7D93FC

Q37200466-2097C85F-86CF-4AB3-A079-10548976D679

Q37200466-2D7CC18D-F093-4198-B2AA-8E992A058D8E

P304

Q37200466-4674D8EF-D4B3-4BCE-99CF-83E51E098EE8

P31

Q37200466-1ADCFF5A-84CB-4E8C-AE7F-BB2168EE1071

P356

Q37200466-5BB83050-A226-40A7-8563-11556665963C

P433

Q37200466-135F6CD4-C2E3-4377-A253-C24CBEFE1E0F

P478

Q37200466-CC5A076B-46DF-40C6-8AB9-034E89BFE1AF

P577

Q37200466-05862AF9-0A89-4ECD-BE87-752692DA7B54

P5875

Q37200466-D2DEBAD8-58C0-4D76-8321-90258A7A61ED

P698

Q37200466-DC018673-8121-41C6-89B4-0C3A1BDDE8A9

P921

Q37200466-39FE20C6-3199-4E47-8196-7DAB5A93B97A

P932

Q37200466-C7D7B3A2-4743-43C6-8D20-FF2A5971879E

P356

P1433

P1476

A rationally designed histone ...... tivity against ovarian cancer.

@en

P2093

Ching-Shih Chen

http://www.w3.org/2001/XMLSchema#string

Curt Balch

http://www.w3.org/2001/XMLSchema#string

Kenneth P Nephew

http://www.w3.org/2001/XMLSchema#string

Michael R Mand

http://www.w3.org/2001/XMLSchema#string

Samuel K Kulp

http://www.w3.org/2001/XMLSchema#string

Ya-Ting Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

The transcriptional targets of p53 in apoptosis control

Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

Cyclin B1 and CDK1: nuclear localization and upstream regulators

Acetylation: a regulatory modification to rival phosphorylation?

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

P304

552-63, 3 p following 563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.09204

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26255013

http://www.w3.org/2001/XMLSchema#string

P698

19484144

http://www.w3.org/2001/XMLSchema#string

P921

P932

2685444

http://www.w3.org/2001/XMLSchema#string